Drapolene contains benzalkonium chloride and cetrimide, which are both quaternary ammonium disinfectants with properties that are typical of cationic surfactants. This preparation is useful in the treatment and prevention of nappy rash. It suppresses the development of ammonia-producing organisms usually associated with this condition

Kamillosan contains chamomile, which soothes redness, soreness and inflammation associated with a wide range of skin conditions.

An intensive natural acne spray formulated to deal with moderate to severe acne on the face and body. It is 97% natural, with sea buckthorn for skin rejuvenation and healing, rosemary for skin toning and cell regeneration, and lavender for its antibacterial and balancing properties

Cimzia (certolizumab pegol) has a high affinity for human TNFα and binds with a dissociation constant (KD) of 90 pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. Cimzia selectively neutralises TNFα (IC90 of 4 ng/ml for inhibition of human TNFα in the in vitro L929 murine fibrosarcoma cytotoxicity assay) but does not neutralise lymphotoxin α (TNFβ). Cimzia was shown to neutralise membrane associated and soluble human TNFα in a dose-dependent manner. Incubation of monocytes with Cimzia resulted in a dose-dependent inhibition of lipopolysaccharide (LPS)-induced TNFα and IL1β production in human monocytes. Cimzia does not contain a fragment crystallisable (Fc) region, which is normally present in a complete antibody, and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro. It does not induce apoptosis in vitro in human peripheral blood-derived monocytes or lymphocytes, or neutrophil degranulation.

Bimekizumab is a humanised IgG1/κ monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines, blocking their interaction with the IL-17RA/IL-17RC receptor complex. Elevated concentrations of IL-17A and IL-17F have been implicated in the pathogenesis of several immune-mediated inflammatory diseases including plaque psoriasis. Bimekizumab inhibits these proinflammatory cytokines, resulting in the normalization of skin inflammation and as a consequence improvement in clinical symptoms associated with psoriasis. From in vitro models, bimekizumab was shown to inhibit psoriasis-related gene expression and cytokine production to a greater extent than inhibition of IL-17A alone.

Dermatonics Once Callus Removing Balm can be applied once or twice daily as prescribied. It combines 25% urea with ceramide rich Oat Lipd Oil and can treat callus and anhidrosis anywhere on the body. Free of parabens.

Ultraveen Itch Relief Cream synergistically combines 5% urea with Colloidal Oatmeal to provide rapid itch relief.

Dermatonics Once Heel Balm, which requires just once daily application, is a 25% urea-based moisturiser with a modern carrier base. It has a less greasy feel and absorbs easily to reduce callus and anhidrosis quickly and effectively. Free of parabens.

10% urea-based moisturiser with a modern carrier base. It absorbs easily to reduce callus and anhidrosis quickly and effectively. Free of parabens.

Hard skin remover cream with urea 7%, salicyclic acid, 4% and trichioroacretic acid 2%. A triple action formula which removes dead skin cells, promotes new growth with an aloe vera base for rapid absorption and increased hydration